PMID- 8388588
OWN - NLM
STAT- MEDLINE
DCOM- 19930624
LR  - 20221007
IS  - 0300-8916 (Print)
IS  - 0300-8916 (Linking)
VI  - 79
IP  - 1
DP  - 1993 Feb 28
TI  - Concurrent carboplatin (CBDCA), vindesine (VDS) and radiotherapy in stage III non 
      small cell lung cancer (NSCLC).
PG  - 49-52
AB  - AIMS: Aim of the study was to test, in a cooperative and prospective trial, the 
      effectiveness and feasibility of a chemoradio-therapy program in stage III non 
      small cell lung cancer (NSCLC). METHODS: The schedule consisted in carboplatin 
      (CBDCA) 150 mg/m2/iv on days 1, 3, 5 and vindesine VDS 2.5 mg/m2/iv on days 1, 8, 
      15, 22 every 4 weeks for 2 cycles followed by radiotherapy 60 Gy with CBDCA 50 
      mg/m2 weekly as radioenhancer. The same schedule was proposed as neoadjuvant 
      treatment in 10/47 patients (stage III A) and as exclusive treatment in 37/47 
      (stage III B) admitted patients. RESULTS: In the neoadjuvant subgroup partial 
      remission was obtained in 5/10 patients, and 3 of them underwent surgery with 
      consequent CR. In the stage III B subgroup, 2 complete remissions were obtained 
      (survival 14 and 9+ months). Toxicity was mild. CONCLUSIONS: Our results confirm 
      the feasibility of the schedule in stage III NSCLC.
FAU - Tomirotti, M
AU  - Tomirotti M
AD  - Dept. of Medical Oncology, Fatebenefratelli-Oft. Hospital, Milan, Italy.
FAU - Gramegna, G
AU  - Gramegna G
FAU - Mantellini, P
AU  - Mantellini P
FAU - Fossati, V
AU  - Fossati V
FAU - Mezzetti, M
AU  - Mezzetti M
FAU - Dimaiuta, M
AU  - Dimaiuta M
FAU - Scanni, A
AU  - Scanni A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - BG3F62OND5 (Carboplatin)
RN  - RSA8KO39WH (Vindesine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/drug 
      therapy/mortality/pathology/radiotherapy/*therapy
MH  - Chemotherapy, Adjuvant
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Feasibility Studies
MH  - Humans
MH  - Lung Neoplasms/drug therapy/mortality/pathology/radiotherapy/*therapy
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - Radiotherapy Dosage
MH  - Vindesine/administration & dosage
EDAT- 1993/02/28 00:00
MHDA- 1993/02/28 00:01
CRDT- 1993/02/28 00:00
PHST- 1993/02/28 00:00 [pubmed]
PHST- 1993/02/28 00:01 [medline]
PHST- 1993/02/28 00:00 [entrez]
AID - 10.1177/030089169307900111 [doi]
PST - ppublish
SO  - Tumori. 1993 Feb 28;79(1):49-52. doi: 10.1177/030089169307900111.